ArticleFrontiers in medicine2022
Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Introduction of DNA-HPV test in the Brazilian cervical cancer screening program: When the idea is good but does not fit the budget.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Observational
- Article
- An entropy-based framework for genomic variability analysis: A South American case study of human papillomavirus.PloS one · 2026Article
- Short-term repeat HPV testing for triaging HPV-positive women in cervical cancer screening.British journal of cancer · 2025Observational
- Accelerating HPV-related cancer elimination - a meeting report.BMC proceedings · 2025Article
- High-risk human papillomavirus testing for underscreened populations: cost-effectiveness and affordability in three country settings.BMC public health · 2025Article
- Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Cost-effectiveness of approaches to cervical cancer screening in Malawi: comparison of frequencies, lesion treatment techniques, and risk-stratified approaches.BMC health services research · 2024Article
- Article
- Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study.Lancet regional health. Americas · 2023Article
- Cervical Cancer Screening Recommendations: Now and for the Future.Healthcare (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 18 institutions in 12 countries.
Funding
Abstract
Background: Replacement of cytology screening with HPV testing is recommended and essential for cervical cancer elimination. HPV testing for primary screening was implemented in 12 laboratories within 9 Latin American countries, as part of the ESTAMPA cervical cancer screening study. Our observations provide information on critical operational aspects for HPV testing implementation in diverse resource settings. Methods: We describe the implementation process of HPV testing in ESTAMPA, focusing on laboratory aspects. We assess the Results: Seven of 12 laboratories had Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.